



Kingdom of Saudi Arabia
Saudi Food & Drug Authority

Saudi Drug Updates (SDU)

Nov 2025 A monthly electronic bulletin published by the drug sector

Drug Safety Updates

Safety Alerts signal communications

The summary includes reviewed safety signals by SFDA:

Product Name	Signal
Furosemide	Risk of Cellulitis
Sertraline	Risk of Cardiac arrest
Sorafenib	Risk of Multiple Organ Dysfunction Syndrome
Risankizumab	Risk of Neutropenia
Dasabuvir	Risk of Increased appetite
Atorvastatin	Risk of Anxiety
Adalimumab	Risk of Antiphospholipid syndrome
Onasemnogene	Risk of Hypercalcaemia
Lenvatinib	Risk of Tumour lysis syndrome
Adalimumab	Risk of Osteonecrosis
Cytarabine	Risk of Palmar plantar erythrodysaesthesia syndrome